Evotec SE (EVO) has reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (BMY) resulting in payments of $40 million to the company. The collaboration was started in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. The collaboration leverages Evotec's industrialised iPSC platform using patient-derived disease models.
Evotec said these target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.